Clinical observation of 125I seed implantation combined with amlotinib hydrochloride in the treatment of advanced non-small cell lung cancer
10.3760/cma.j.cn121382-20210305-00404
- VernacularTitle:125I粒子植入联合盐酸安罗替尼治疗晚期非小细胞肺癌的临床疗效观察
- Author:
Yijie YAN
1
;
Jun ZHANG
;
Shuo WANG
;
Fanjie MENG
;
Bin WANG
;
Zhiyu GUAN
Author Information
1. 天津医科大学第二医院胸外科 300211
- Keywords:
Non-small cell lung cancer;
125I seeds implantation;
Anlotinib
- From:
International Journal of Biomedical Engineering
2021;44(4):277-280,285
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of 125I seed implantation combined with anlotinib hydrochloride in the treatment of non-small cell lung cancer (NSCLC). Methods:61 cases of NSCLC patients were enrolled, of which 30 cases (observation group) received 125I seed implantation combined with anlotinib treatment, and 31 cases (control group) received 125I seed implantation only. To evaluate the curative effect and adverse reactions of all patients, the carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuroendocrine enolase (NSE), squamous cell carcinoma antigen (SCC) in the peripheral blood of the two groups was measured before the treatment and at 1 and 3 months after the treatment. Results:The effective rates in the observation group were 90.00% and 93.33%, the effective rates in the control group were 67.74% and 74.19% at 1 and 3 months after the treatment, respectively, and the difference in efficacy between the two groups was statistically significant ( χ2=4.504, P=0.034 vs. χ2=4.075, P=0.044). There was no significant difference in the incidence of adverse reactions between the two groups of patients after treatment ( P=0.785). At 1 and 3 months after the treatment, the levels of CEA, CYFRA21-1, NSE and SCC in the peripheral blood of the two groups of patients were lower than those before the treatment (all P<0.05). Conclusions:125I seed implantation combined with anlotinib hydrochloride is safe for the treatment of advanced non-small cell lung cancer, and has promotion value.
